Etesevimab 700 mg in 20 mL Injection (EUA)
RxNorm 2477902

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2477902 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: etesevimab 700 mg in 20 mL Injection (EUA).

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
20 mL etesevimab 35 mg/ML Injection
Primary clinical definition
AUI:12538837
View
PSN
Etesevimab 700 mg in 20 mL Injection (EUA)
AUI:12538839
View
SY
Etesevimab 700 mg per 20 mL Injection (EUA)
AUI:12538840
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCD

Semantic Clinical Drug (SCD):
20 mL etesevimab 35 mg/ML Injection
(Atom ID: 12538837)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
20 ML etesevimab 35 MG/ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2477902
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12538837
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
2477902
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2477899} 2477854
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2477899} 2477854
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2477899} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN OBSOLETED
11/24/2025
Date the RxNorm atom became obsolete
RXN QUANTITY
20 ML
Normal Form quantity factor
PSN

Prescribable Name (PSN):
Etesevimab 700 mg in 20 mL Injection (EUA)
(Atom ID: 12538839)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
etesevimab 700 MG in 20 ML Injection (EUA)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2477902
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12538839
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2477902
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SY

Synonym (SY):
Etesevimab 700 mg per 20 mL Injection (EUA)
(Atom ID: 12538840)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
etesevimab 700 MG per 20 ML Injection (EUA)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2477902
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12538840
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2477902
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Bamlanivimab and Etesevimab Injection


The combination of bamlanivimab and etesevimab injection is used to treat COVID-19 infection in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have mild to moderate COVID-19 symptoms. They are used in people who have certain medical conditions such as diabetes, immunosuppressive conditions, or kidney, heart, or lung disease that put them at higher risk for developing severe COVID-19 symptoms and/or needing to be hospitalized from COVID-19. Bamlanivimab and etesevimab are in a class called monoclonal antibodies. These medications work by blocking the action of a certain natural substance in the body to stop the spread of the virus.
[Learn More]


* Please review the disclaimer below.